Online GLP-1 Programs in Louisiana

Insurance

Does Louisiana Medicaid cover GLP-1s?

Louisiana Medicaid covers GLP-1s for type 2 diabetes and for obesity only when paired with a co-occurring condition such as diabetes, sleep apnea, or heart failure, not for weight loss alone (The Advocate, 2026; RX Index, 2026). A 2026 bill (SB 433) would add standalone obesity coverage for adults with a BMI of 35 or higher, or 30 or higher with a comorbidity, effective 2027 if enacted and funded, with the state estimating about 145,000 enrollees would qualify. For now, weight-loss-only coverage is not available.

Online Access

Getting a GLP-1 online in Louisiana

GLP-1s are not controlled substances, so Louisiana allows them to be prescribed via telehealth without a mandatory in-person exam, provided a Louisiana-licensed clinician establishes a valid relationship (Louisiana R.S. 40:978). Online programs can serve residents statewide.

Compounding

Compounded semaglutide & tirzepatide in Louisiana

Routine compounding of semaglutide and tirzepatide ended after the FDA resolved the shortages in early 2025 (FDA, 2025). Louisiana adds no special carve-out beyond the federal 503A/503B framework, so compounding is limited to documented, patient-specific clinical need.

Demand

Where GLP-1 demand is highest in Louisiana

Louisiana has the third-highest adult obesity rate in the nation, around 39%, and a diabetes rate near 15% (CDC BRFSS via America's Health Rankings, 2024). Demand is high across New Orleans, Baton Rouge, and Shreveport. With Medicaid covering GLP-1s for obesity only alongside another condition, and a coverage-expansion bill still pending, much of that weight-loss demand runs through cash-pay and telehealth.

Questions

Louisiana GLP-1 FAQ

Compound Guides

The GLP-1s behind these programs

Sources

How we sourced this page

Coverage, prevalence, and policy figures are drawn from primary and authoritative sources, last reviewed June 2026.